Importantly, GLP-1 RAs appear to reduce the risk of major adverse cardiovascular events, microvascular complications, and mortality in patients with T2D (Dicembrini et al., 2017; Bethel et al., 2018; Giugliano et al., 2019; Zelniker et al., 2019). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.